GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orchard Therapeutics PLC (NAS:ORTX) » Definitions » 14-Day RSI

Orchard Therapeutics (Orchard Therapeutics) 14-Day RSI : 85.36 (As of May. 05, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Orchard Therapeutics 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-05), Orchard Therapeutics's 14-Day RSI is 85.36.

The industry rank for Orchard Therapeutics's 14-Day RSI or its related term are showing as below:

ORTX's 14-Day RSI is not ranked
in the Biotechnology industry.
Industry Median: 48.86 vs ORTX: 85.36

Competitive Comparison of Orchard Therapeutics's 14-Day RSI

For the Biotechnology subindustry, Orchard Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orchard Therapeutics's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orchard Therapeutics's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Orchard Therapeutics's 14-Day RSI falls into.



Orchard Therapeutics  (NAS:ORTX) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orchard Therapeutics  (NAS:ORTX) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Orchard Therapeutics 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Orchard Therapeutics's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Orchard Therapeutics (Orchard Therapeutics) Business Description

Traded in Other Exchanges
Address
245 Hammersmith Road, London, GBR, W6 8PW
Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. It operates in three geographic regions: the United Kingdom, European Union, and the United States. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.
Executives
Bobby Gaspar director, officer: See Remarks ORCHARD THERAPEUTICS PLC, 108 CANNON STREET, LONDON X0 EC4N 6EU
Fmr Llc 10 percent owner, other: See Remark 1 245 SUMMER STREET, BOSTON MA 02210
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Steven Altschuler director MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026
Jon Ellis director ORCHARD THERAPEUTICS PLC, 108 CANNON STREET, LONDON X0 EC4N 6EU
Plc Glaxosmithkline director, 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Marc Dunoyer director ORCHARD THERAPEUTICS PLC, 108 CANNON STREET, LONDON X0 EC4N 6EU
John T Curnutte director PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Rowland Charles A Jr director 3338 LANCASHIRE RD, FURLONG PA 18925
Mark Rothera director, officer: See Remarks C/O AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
James A Geraghty director C/O IDERA PHARMACEUTICALS, INC., 167 SIDNEY STREET, CAMBRIDGE MA 02139
Alicia Secor director 33 HAYDEN AVE., LEXINGTON MA 02421

Orchard Therapeutics (Orchard Therapeutics) Headlines

From GuruFocus

Kyowa Kirin to Acquire Orchard Therapeutics

By Marketwired 10-05-2023